INTRODUCTION

Prostate cancer (PCa), as the leading type of diagnosed malignancy in men, imposes a significant health burden for the male population globally. As demonstrated in previous studies, androgens play a pivotal role in the survival and growth of PCa cells by activating the androgen receptors (AR). Most prostate tumours require androgens for progression at early stages; however, over time, most prostate tumours become androgen-refractory with more aggressive and metastatic characteristics due to alterations in AR expression downstream signalling pathways. These androgen-refractory tumours do not further respond to androgen depletion therapy and a variety of cytotoxic drugs. Currently, no established and effective treatment has been identified to prolong the survival of patients with these
tumours. Therefore, the detection of new therapeutic measures is of utmost importance for managing PCa tumours.

Arsenic trioxide (ATO) is an anticancer agent primarily employed to induce remission in patients with acute promyelocytic leukaemia. The therapeutic efficacy of ATO in leukaemic patients has encouraged researchers to investigate its utility in other neoplasms and solid tumours, including PCa. In this regard, previous studies have demonstrated the capability of ATO to decrease cell proliferation, induce apoptosis and autophagy, and inhibit AR activity in PCa cell lines. Moreover, ATO demonstrates anti-angiogenic properties through modulation of transforming growth factor-beta (TGF-β)/SMAD signalling pathway. However, previous studies have reported toxicity resulting in acute and chronic side effects following treatment with ATO. Thus, strategies for reducing the therapeutic dose and diminishing the adverse effects of ATO in managing prostate tumours are crucial. Combination therapy could be one of those strategies for reducing ATO toxicity and enhancing its therapeutic efficacy.

Statins, a class of lipid-lowering drugs via inhibiting β-hydroxy β-methylglutaryl-coenzyme A (HMG-CoA) reductase, have been linked to reduced risk of PCa, particularly the advanced disease. Cell-based and animal-based investigations have described the anti-carcinogenic effects of statins in PCa through both cholesterol-mediated and non-cholesterol-mediated mechanisms. The anti-neoplastic roles of statins include inhibition of neoplastic cell proliferation, migration, invasion and pathological angiogenesis, alongside promoting apoptosis. Statins’ family have different intracellular effects, pravastatin and rosuvastatin (hydrophilic statins), simvastatin (lipophilic statins) display a greater ability to penetrate the cell membrane. Since lipophilic statins have higher pro-apoptotic activity and cytotoxic potential than hydrophilic statins and may be beneficial in cancer treatment, in this study, we used simvastatin to evaluate its effect on prostate cancer cells.

In addition, accumulating evidence has suggested that statins downregulate AR expression in PCa cells, leading to a significant reduction in serum prostate-specific antigen (PSA). Given these anti-neoplastic effects, statins have been utilized with other anti-PCa regimens in several reports. However, to the best of our knowledge, no prior studies have investigated the combined effect of ATO and statins on PCa. Moreover, the evidence regarding the role of ATO in the management of prostate tumours is limited. Hence, we aimed to study the effects of ATO, Simvastatin, and their combination in both androgen-dependent (LNCaP) and androgen-independent (PC3) cell lines of PCa in terms of proliferation, apoptosis and pathological angiogenesis.

2 MATERIALS AND METHODS

2.1 Cell lines and cell culture

LNCaP (ATCC Number: CRL-10995 and NCBI Code: C439) and PC3 (ATCC Number: CRL-1435 and NCBI Code: C427) were obtained from the National Cell Bank of Pasteur Institute (Tehran, Iran). Both prostate cancer cell lines were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA), which was supplemented with 10% and 20% heat-inactivated FBS (Gibco, Carlsbad, CA), 100 units/mL of Penicillin, 2 mM L-glutamine and 100 μg/mL of Streptomycin (Gibco BRL, Grand Island, NY). Both prostate cancer cells were incubated at 37°C in a humidified atmosphere containing 5% CO₂. Simvastatin was dissolved in DMSO and then dissolved in sterile double-distilled water. ATO was dissolved in distilled water.

2.2 Cell viability assay

LNCaP and PC3 prostate cancer cell lines were treated with different doses of Simvastatin, and ATO with different concentrations (0-14 μM) were compared with the control group following 24, 48 and 72 h after treatment. The anti-proliferative effect of these two drugs on cell survival was measured in a dose- and time-dependent manner. Briefly, both prostate cancer cell lines were seeded 5 x 10⁵ cells per well in a 96-well plate. The experiment was accomplished in triplicate to determine the anti-proliferative effect of the half-maximal inhibitory concentration (IC50) of two drugs against the prostate cancer cell lines. In a microplate reader, the optical density was read at an absorbance of 570 nm wavelength (Hyperion, GmbH & Co. KG). Dose-response curves were plotted, and IC50, an inhibitory concentration of 50% of the control cell’s growth was calculated by GraphPad PRISM software version 6 (San Diego, CA). Outcomes were evidenced as a proliferation rate, with 100% representing control cells treated with 0.1% DMSO alone.

2.3 Evaluation of cell morphology by crystal violet staining

LNCaP and PC3 prostate cancer cell lines (5 x 10⁵) treated with IC50 concentrations of Simvastatin and ATO for 48 h were implanted in a six-well plate. Both cell lines were washed twice with PBS and then fixed with −20 methanol and stained the cells with 0.5% w/v crystal violet solution. Cell morphology was evaluated using a reverse microscope.

2.4 In vitro 3D colony formation assay

Colony Forming Assay was completed to estimate the invasiveness of prostate cancer cells in vitro. We prepared 2% and 0.7% sterile agarose for this protocol and stored them in a water bath at 45°C. LNCaP and PC3 prostate cancer cells (2 x 10⁵ cells/well) were seeded in six-well plates followed by ATO and Simvastatin treatment with desired concentrations (12 μM Simvastatin/8 μM ATO for PC3 and 8 μM Simvastatin/5 μM ATO for LNCaP), cells are poured on 2% agar. RPMI-1640 medium with 10% FBS and 0.7% agarose was added to the cells. The plate was incubated at 37°C until cells grew to visible colonies, and after 14 days, washed with PBS twice and then, colonies were stained with 0.5% w/v.
crystal violet solution for 30 min at 25°C. Each well was examined for colony formation (Cells accumulate 50 or more cells) under an inverted microscope. All experiments were carried out independently three times.

2.5 | Hoechst dye (33342) staining

Hoechst dye assay was used to estimate the apoptosis of prostate cancer cell lines in vitro. Both prostate cancer cell lines were seeded into a 24-well plate (5 × 10^5 cells/well), then added desired concentrations of ATO, Simvastatin, and their combinations. After 72 h of incubation, the control and treated cells were fixed with 200 μl of methanol and placed at −20°C for 15 min. After centrifugation, PBS (50 μl) and Hoechst dye (2 μl) were added to the cell precipitate and incubated (30 min) at 25°C in the dark. A drop of each sample was placed on a slide and observed and imaged using a fluorescence microscope at 100 magnifications.

2.6 | Measurement of cell migration

LNCaP and PC3 prostate cancer cell lines were cultured at 5 × 10^5 cells per well in a six-cell culture dish. After the cells reached a density of 85%, using a sampler tip, a vertical line was created along the diameter of the six cells. For removing the isolated cells, the bottom of the culture dish was gently washed with a serum-free culture medium. After 24 h of exposing the cells to the serum-free culture medium, some cells were treated with deionized water as a control group and some others were treated with the drugs (ATO and Simvastatin treatment, PC3 cell: 12 μM Simvastatin/8 μM ATO and, LNCaP cell: 8 μM Simvastatin/5 μM ATO). Then, at zero and 24 h, apoptosis was determined as a percentage of the annexin V- positive cells through flow cytometry by BD flow cytometer instrument and analysed with flowjo program (Tree Star Inc., version 9.6.3, USA).

2.8 | DNA cell cycle flow cytometry analysis

Cell cycle distribution was accomplished using Propidium Iodide staining. Both prostate cell lines PC3 and LNCaP (5 × 10^5 cells/well) were seeded into 6-well plates, permeabilized and treated with desired concentrations of Simvastatin and ATO for 48 h then washed with PBS twice, fixed with 70% cold ethanol and stored at −20°C overnight. Next, cells were washed with PBS twice and incubated at 37°C for 30 min with RNase I (100 μg/ml) and dye DNA with 500 μl propidium iodide (PI) (50 μg/ml in 0.1% Triton X-100/0.1% sodium citrate). A BD flow cytometer set separated cells. The DNA content was analysed using flow cytometry, and the results were analysed with the Flowjo software (Tree Star Inc., version 9.6.3, USA). The apoptotic cell fraction could predict from the hypodiploid sub-G0/G1 DNA fraction.

2.9 | RNA isolation and real-time PCR

According to the manufacturer’s instructions, total RNA was extracted by the Highly Pure RNA isolation kit (Roche Applied Science, Germany). First, the quality and quantity of total RNA were assessed spectrophotometrically using Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE) at 260 and 280 nm. Next, according to the manufacturer’s instructions, complementary DNAs (cDNAs) were reverse transcribed from 1 to 2 μg of total RNA using a cDNA synthesis PrimeScript RT reagent Kit (Takara Bio Inc., Otsu, Japan). The cDNA concentration was then normalized in a series of PCR by using GAPDH primers (Table 1). Finally, the normalized cDNAs were subjected to amplification using QIAGEN’s real-time PCR cycler. GAPDH was used as the housekeeping gene to normalize the expression levels, and the 2^-ΔΔCT method was used to calculate the relative expression. The list of the used primers and their corresponding amplicon lengths are provided in Table 1.

2.10 | Statistical analysis

All data were provided as means ± standard deviation (SD) of triplicate measurements. Analysis of variance ANOVA method, and t-test,
**TABLE 1** Nucleotide sequences of primers used for real-time PCR

| Gene     | Accession number | Forward primer (5′−3′)                  | Reverse primer (5′−3′)                  | Size (BP) |
|----------|------------------|----------------------------------------|----------------------------------------|-----------|
| OPN-A    | NM_001040058.1   | ATCTCCTAGCCCCACAGAAT CATCAGACTGGTGAGAATCATC | CATCAGACTGGAAGCTGCAATCAG               | 208       |
| OPN-B    | NM_000582.2      | ATCTCCTAGCCCCAGAGAC AAAATCAGTGACCAGTTCATCAG | GTCATGGGAGTAGGCTTGCTGT                | 209       |
| OPN-C    | NM_001040060.1   | TGAGGAAAAGCAGAATGCTG GTCAATGGAGTCCTGGCTGT | GTCATGGGAGTAGGCTTGCTGT                | 155       |
| BCL-2    | NM_000633.3      | GGGGAGGATTGTGGCCTTC CAGGGCGATGTTGTCCACC | GCTAGCCCTCTGTTTGACG                  | 90        |
| BAX      | NM_001291428.2   | GATGCCGTCCAAGAAAGAC CCAGTTGAAGTTGCCGTCAG | ATCTTGACTGGAAGCTGCAATCAG             | 165       |
| P53      | NM_000546.6      | AGACCTATGGAAACTACTTC GGACAGCATCAAATCATC | GGACAGCATCAAATCATC                  | 76        |
| PTEN     | NM_000314        | ACCAGGACCAGGAAACCT GCTAGCCCTCTGTTGACG | GCTAGCCCTCTGTTTGACG                  | 135       |
| VEGF-A   | NM_001316955.1   | CTCACCAAGGCCCAGCAGCATAGG ATCTTGACTGGAAGCTGCAATCAG | ATCTTGACTGGAAGCTGCAATCAG             | 159       |
| VEGF-C   | NM_005429.4      | GTCTGTGCCAGTGTGAATG GTCTGTGCCAGTGTGAATG | AGTGATGTCGTCGCGTGGTTT                | 360       |
| GAPDH    | NM_001289746.1   | GTGAACTGAGAAGATGACAGAC CATGAGTCCTTCCACGATACC | CATGAGTCCTTCCACGATACC              | 123       |

**FIGURE 1** Evaluation of cell morphology by crystal violet staining of prostate cancer PC3 and LNCap cell lines. Untreated PC3 and LNCap cells (A, B). PC3 and LNCap cells treated with eight and 5 μM ATO (C, D). PC3 and LNCap cells treated with 12 and 8 μM Simvastatin (E, F). PC3 cells treated with 12 μM Simvastatin plus 8 μM ATO (G), LNCap cells treated with 8 μM Simvastatin and 5 μM ATO (H). Colony formation assay in PC3 cells. Cells were treated with 12 μM Simvastatin and 8 μM ATO at six-well plates and were cultured for 14 days and stained with crystal violet. Colonies showed as overview images, from left to right, respectively, were control cells without treatment (I), treatment with 12 μM Simvastatin (J), treatment with 8 μM ATO (K), and finally, combination therapy with both drugs 12 μM Simvastatin and 8 μM ATO (L) resulted in a significant discount in the number of colonies. These figures endorse that Simvastatin and ATO alone and in combination decrease the metastatic effect of PC3 cells and are very effective in inhibiting migration. Scheme of forming a colony containing 50 or more cells (M)
were used to estimate the outcomes, and a significance level of 95% was considered. Statistical significance was defined at * \( p < 0.05 \), ** \( p < 0.01 \), and *** \( p < 0.001 \) compared to the corresponding control.

## 3 | RESULTS

### 3.1 | ATO/Simvastatin inhibits cell proliferation

The cytotoxic effects of Simvastatin (0–18 \( \mu M \)) and ATO (0–12 \( \mu M \)) alone and in combination were evaluated in two distinct prostate cancer cell types. Growth inhibitory effects of different concentrations of ATO, Simvastatin, or their combination were evaluated by MTT for 24, 48, and 72 h (Figure 1). Based on the results, IC\(_{50}\) values for ATO were 8 and 5 \( \mu M \) for PC3 and LNCaP cells; IC\(_{50}\) values for Simvastatin were 12 and 8 \( \mu M \) for PC3 and LNCaP cells respectively. The results showed that ATO and Simvastatin had a significant cytotoxic effect on both cell lines in a dose- and time-dependent manner. On the other hand, treatment of PC3 and LNCaP cells with 12/8 \( \mu M \) Simvastatin and 8/5 \( \mu M \) ATO caused a significant reduction in the number of colonies. These data showed that Simvastatin and ATO alone and in combination reduce the proliferation of PC3 and LNCaP cells and effectively reduce their viability (Figure 2).

### 3.2 | Induction of apoptosis by ATO/Simvastatin

We performed a flow cytometry assay to investigate apoptotic effects of ATO and Simvastatin on PC3 and LNCaP cell lines. Compared with ATO and Simvastatin alone, the results showed a significant apoptotic increase in PC3 and LNCaP cells treated with combined ATO and Simvastatin, compared with ATO and Simvastatin alone (Figure 3). In addition, we detected an increase in the number of early and late apoptotic cells (annexin+/ PI-, +) and the minimum percentage of necrosis (annexin+/PI+) in treated cells compared with control in both cell lines. Furthermore, a significant 85% increase in apoptotic cells was seen in PC3 cells treated with a combination of ATO and Simvastatin.

More apoptosis was seen when ATO was first added to the prostate cancer cell lines than when Simvastatin was first added to both cells. In addition, more apoptosis and necrosis were seen when ATO was first added to the prostate cancer cell lines for 48 h and then 24 h after Simvastatin than when ATO was first added to both cancer cell lines for 24 h and then 24 h after Simvastatin. On the other hand, the effect of drugs (apoptosis) on the PC3 cell line was much more than LNCaP for both (24+24)48 and (48+24)72 h (Figure 4).

### 3.3 | ATO/Simvastatin induces subG1/G1 arrest in PC3 and LNCaP cells

Cell cycle flow cytometry analysis was applied for PC3 and LNCaP cells treated with ATO and Simvastatin and their combination with respect to inducing cell cycle arrest (Figure 5). Among the control LNCaP cells, cells in stages sub-G1, G1, S and G2 accounted for 4.69%, 50.98%, 34.01% and 10.32% of the total cell population respectively. The Simvastatin therapy resulted in increase in sub-G1 cells (4.69%-27.33%) and decrease in G1 (50.98%-49.25%), S (34.01%-13.17%) and G2 (10.32%-10.25%) cells. Additionally, treatment with ATO resulted in the elevation of sub-G1 cells (4.69%-19.58%) and reduction of cells in G1 (50.98%-43.95%), S (34.01%-30.61%) and G2 (10.32%-5.86%) phases. The combination therapy of Simvastatin and ATO led to a more prominent rise in sub-G1 cells (4.69%-32.35%) and a subsequent decrease in G1, S and G2 cells.

The results regarding the PC3 cells were similar with an increase in sub-G1 phase cells following the administration of Simvastatin (3.73%-15.61%), ATO (3.73%-25.89%) and their combination (3.73%-36.50%), alongside the decline in the following cell cycle phases.

The results revealed that the cells treated with ATO and Simvastatin significantly stopped the cell cycle in the sub-G1/G1 phase compared with the control group. Moreover, the presence of this sub-G1 peak after the drug therapy was indicative of increased apoptosis.

### 3.4 | Effects of ATO and Simvastatin on the nucleus of PC3 and LNCaP cell lines

The results of the Hoechst 33342 fluorescent dye are displayed in Figure 6. The nuclei of the control group showed blue fluorescence. After treatment with ATO or Simvastatin, noticeable changes in the nuclei morphology were observed. Many nuclei split and disintegrated after the cells were treated with 12 \( \mu M \) Simvastatin/8 \( \mu M \) ATO for PC3 and, 8 \( \mu M \) Simvastatin/5 \( \mu M \) ATO for LNCaP cell. As a result, the nuclear contents were dispersed. In addition, apoptosis features were observed under a fluorescent microscope (Figure 6).

### 3.5 | Effects of ATO and Simvastatin on the migration of the prostate cancer cells

The results of the migration assay are shown in Figure 6. As shown in Figure 6, ATO and Simvastatin have dramatically inhibited the migration of prostate cancer cells after the cells were treated with 8 \( \mu M \) ATO/12 \( \mu M \) Simvastatin for PC3 cell line and, 5 \( \mu M \) ATO/8 \( \mu M \) Simvastatin for LNCaP cell line. However, in the control group, the space created between the cells is completely filled.

### 3.6 | Effect of Simvastatin and ATO on gene expression levels in LNCaP and PC3 cells

LNCaP and PC3 cells were treated with Simvastatin and ATO for 48 h and then examined for Osteopontin (OPN) isoforms and
Simvastatin and ATO with different concentrations (0–14 µM) on cell proliferation. The anti-growth effect of cited drugs and their combination was measured by MTT assay following 24, 48, and 72 h in LNCaP and PC3 cell lines. IC50 pharmaceutical doses of 8 and 12 µM in PC3 cell line and 5 and 8 µM in LNCaP cell line for ATO and Simvastatin were determined respectively. Data displayed that the anti-proliferative impact of these drugs reduces viability and a variety of cells during a dose- and time-dependent manner. A combination of mentioned drugs was highly influential in inhibiting cell growth and promoting enormous programmed cell death in each cell line. MTT assays are presented as the mean ± SD of three independent experiments. Statistical significance was defined at *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the corresponding control.
angiogenesis genes (vascular endothelial growth factor (VEGF) A and C) and apoptosis genes (Bcl-2, BAX, P53 and PTEN) expression by Real-Time PCR.

ATO and Simvastatin had a synergistic apoptotic effect on LNCaP and PC3 cells by up-regulation of P53/PTEN and down-regulation of the BAX/Bcl-2 (Figure 7); hence, ATO may act as a potential anti-cancer agent against LNCaP and PC3 cells through triggering the mitochondrial pathway of apoptosis.

ATO and Simvastatin each alone increase BAX and decrease Bcl-2 expression, and this effect is significantly increased in combination therapy (Figure 7). Likewise, BAX/Bcl-2 ratio in combination therapy was significantly higher than the treatment by ATO or Simvastatin alone (Figure 7).

Our data showed that Simvastatin (an HMG-CoA reductase inhibitor) as a natural element for inhibition of OPN significantly decreased OPN gene three isoforms expression in treated groups in both LNCaP and PC3 cell lines (Figure 7). In addition, we observed that in response to treatment with ATO and Simvastatin alone and combination of these two drugs, the expression level of OPN isoforms, VEGF isoforms, and Bcl-2 genes was decreased compared with untreated cells; whereas P53, PTEN and BAX genes had a significant increase in expression in both LNCaP and PC3 cell lines (Figure 7).

4 | DISCUSSION

This study investigated the therapeutic effects of ATO, Simvastatin and their combination in androgen-dependent and androgen-independent cell lines of PCa. Our findings showed that a combination of these two agents could effectively inhibit neoplastic cell proliferation and induce apoptosis, possibly through alterations in the expression of apoptotic genes and regulation of the pro-angiogenic pathways. These results propose a novel combination regimen for managing prostate malignancies, especially for advanced tumours ir- responsive to anti-androgen therapy.
Concerning PCa proliferation, ATO has been determined to contribute to malignant cell death via enhancement of apoptosis.\(^8,10,22-25\) Although the exact mechanisms involved in ATO-induced apoptosis in solid tumours have yet to be ascertained, several cellular processes have been suggested. For example, generation of reactive oxygen species (ROS),\(^{24}\) inhibition of Akt/mTOR signalling pathway\(^{23}\) and activation of p38/caspase 3\(^{24}\) are among several cellular mechanisms identified in apoptosis of PCa cells after ATO administration. In addition, statins have been determined to regulate PCa growth via the regulation of numerous cellular mechanisms, for example decrease in Akt activity,\(^{14,26}\) reduction in intratumoral androgen by lowering cholesterol levels\(^{27}\) and activation of specific proteases involved in apoptosis.\(^{28}\)

Our findings demonstrated that these two drugs and their combination could inhibit proliferation and enhance apoptosis of PCa cells. Furthermore, we observed that this process is mediated via sub G1/G1 cell cycle arrest. Similar to our results, Jadhav et al. previously showed that nanoparticulate formulation of ATO can induce caspase-dependent apoptosis, along with G0-G1 and G2-M phase arrest in LNCaP and PC3 cell lines respectively.\(^{25}\) Additionally, Hoque et al. described that Simvastatin and Lovastatin diminish the cell viability of both androgen-sensitive and androgen-insensitive PCa cells, trigger apoptosis and lead to arrest in the G1 phase.\(^{16}\)

Deng et al examined that Simvastatin and fluvastatin can promote apoptosis and reduce viable and cell proliferation via AKT/FOXO1 signalling pathway and inhibition of MCL-1 studied by Alqudah et al. (2018). Chen et al. (2017) investigated that irinotecan with simvastatin in PC3 and DU145 prostate cancer cell lines and in another study Atorvastatin alone inhibit the expression of HIF-1α protein level and increase hypoxia-induced prostate cancer cells.\(^{31}\) Wang et al. (2020), considered that The combination of caffeine and atorvastatin suppressed tumour spheres, invasion, migration,
proliferation and prompted apoptotic via downregulating phosphorylated Akt, phosphorylated Erk1/2, Bcl-2 and Survivin protein levels. In another research, Zheng et al. (2010), showed that celecoxib with atorvastatin suppressed tumour progression and Akt, Erk1/2 and NF-κB expression in prostate cancer cell. Kochuparambil et al. (2011), confirmed that Simvastatin has anticancer effectiveness on prostate cancer cells and reduced prostate-specific antigen expression and inhibit the Akt expression. Rosuvastatin, mevastatin, simvastatin and atorvastatin decrease the migration and colony formation of metastatic prostate colonies of PC-3 cells via preventing production of geranylgeranyl pyrophosphate.

These antitumor properties of ATO and statins are mainly due to boosted caspase enzymatic activity and suppressed expression of cyclins. The findings of our study combined with previous reports suggest that combination therapy with ATO and Simvastatin can prevent PCa cell proliferation via cell cycle arrest and increased apoptosis. More importantly, these results were achieved with 5µM and 8µM of ATO in LNCaP and PC3 cells, respectively, which are comparable to the previous reports and considered an acceptable dose for in vivo parental administration.

ATO has been described as an effective anticancer and FDA-approved drug for treating some cancers. Our results presented a significant reduction in the survival of the LNCaP and PC3 cells in ATO/Simvastatin-treated groups. As estimated, cell survival was much less in combination treatment than treatment with only Simvastatin or ATO. The results show that ATO and Simvastatin worked additively in inducing cell death and inhibiting LNCaP and PC3 cell proliferation. In addition, the results suggest that combination treatment increases programmed cell death, possibly by enhancing the internal pathway of apoptosis.

To evaluate the possible mechanism of apoptosis induced by the two drugs, we evaluated the expression of apoptotic (BAX) and anti-apoptotic (Bcl-2) genes, and their ratio was considered an indicator of mitochondrial apoptosis response to the drug. We observed
downregulated expression of anti-apoptotic Bcl-2 and upregulation of pro-apoptotic BAX gene, following treatment with ATO, Simvastatin and their combination. This gene expression alteration is associated with the expression of cyclin-dependent kinase inhibitor p21, resulting in increased apoptosis. Similar findings have been identified after ATO therapy in other solid tumours, such as

**FIGURE 6** Hoechst dye (33342) Staining. As seen in the above image, LNCap cell lines treated with 5 μM ATO and 8 μM Simvastatin after 48 h (B) compared with control LNCap cells (A), there are fragmented nuclei cells that designate apoptotic cell, which is clearly within the cell (B1-4). Cell migration assays in prostate cancer PC3 and LNCap cell lines control (C), treated with Simvastatin or ATO (D) and combined Simvastatin and ATO (E). Cells were photographed with 40 magnifications at different time points.
hepatocellular carcinoma, glioma and breast cancer. In addition, Simvastatin has been determined to induce the same apoptotic features in cell lines of numerous malignancies, including breast cancer, lung cancer and gastric carcinoma. The proteins of the Bcl-2 family are involved in programmed cell death through the modulation of mitochondrial function. In fact, changes in the electrical potential of mitochondria under different physiological and pathological processes can lead to the release of apoptotic proteins, for instance, pro-caspases 2, 3 and 9.

ROS generation is postulated to play a pivotal role in mitochondrial oxidative damage, subsequently leading to apoptosis. In this manner, Bcl-2 employs an anti-apoptotic function via a decrease in cellular ROS. Thus, downregulation of Bcl-2 accompanied by the overexpression of BAX favours mitochondrial-mediated apoptosis, resulting from intracellular ROS accumulation. On the other hand, BAX and Bcl-2 are two widely known transcriptional targets of the P53 protein, a tumour suppressor protein in charge of apoptosis and cell cycle arrest in case of DNA damage. In this study, the expression of P53 was upregulated in LNCaP and PC3 cells after therapy with ATO, Simvastatin and their combination, which provides further evidence for increased apoptosis in PCa following this novel regimen.

Moreover, we detected increased expression of the PTEN, a tumour suppressor regulating the PI3K/Akt/mTOR pathway, following treatment with ATO and Simvastatin. The PTEN exerts pro-apoptotic features by several pathways, such as sensitization of PCa cells to death-receptor mediated apoptosis and augmentation of serum starvation-induced apoptosis via inhibition of insulin-like growth factor 1 receptor synthesis. Taken together, the increased expression of BAX, P53, and PTEN alongside the decreased Bcl-2 expression are all in favour of apoptosis and diminished proliferation of PCa cells.

The results of our previous study showed that ATO and flutamide increase the antitumor effect on both prostate cancer cell lines. That study also showed ATO decreases VEGF expression alongside reducing the expression of two genes, KLK2 and Snail (prostate cancer biomarker). This gene expression effect was increased when ATO was combined with flutamide. In addition to the genes involved in apoptosis, we explored two important regulators of angiogenesis (VEGF and OPN). As one of the most potent pro-angiogenic factors with two isoforms (A and C), VEGF is involved in microvascular remodelling, angiogenesis, and subsequently, metastasis and progression of PCa. Furthermore, OPN, an integrin-binding glycosphosphoprotein in the extracellular matrix (with three A, B and C isoforms), can be secreted from malignant cells to increase their metastatic ability by regulating their metastatic capacity, VEGF production and angiogenesis. Based on gene expression analysis, we detected
a significant reduction in the expression of OPN and VEGF isoforms in both LNCaP and PC3 cells after administration of ATO, Simvastatin and their combination.

These findings provide new insight into the anti-angiogenic properties of these two drugs in PCa. Previously, Ji et al. have described that ATO can function as an anti-angiogenic agent in PCa by inhibition of TGF-β/SMAD pathway, which is crucial in VEGF secretion.11 Also, our results align with the study by Al-Husein et al. that indicated a reduction in VEGF-A in PC3 cells following Simvastatin therapy, abrogating the endothelial barrier disruption.48 Besides, Matsuura et al. detected that Simvastatin could provide anticaner effects via a reduction in OPN expression both in vitro and in vivo models.49 All in all, ATO and Simvastatin treatment may provide anti-angiogenic and anti-proliferative properties in PCa.

In conclusion, the findings of this study showed that ATO, Simvastatin and their combination exert anti-neoplastic functions in PCa, possibly by overexpression of pro-apoptotic BAX, PS3, PTEN genes and downregulation of anti-apoptotic Bcl-2 gene. Moreover, these two agents can provide anti-proliferative and anti-angiogenic properties by reducing VEGF and OPN genes. These results provide new perceptions regarding ATO and Simvastatin's combination therapy in PCa, which requires further investigation in animal models and human clinical trials.

ACKNOWLEDGMENTS
Special thanks to Sina hospital, Tehran University of Medical Sciences, Tehran, Iran.

CONFLICTS OF INTEREST
All authors claim that there is not any potential competing or conflict of interest.

AUTHOR CONTRIBUTIONS
Akram Mirzaei: Methodology (supporting); Writing – original draft (lead). Sina Rashedi: Investigation (supporting). Mohammad Reza Akbari: Resources (supporting); Validation (supporting). Fatemeh Khatami: Data curation (supporting); Supervision (supporting). Seyed Mohammad Kazem Aghamir: Conceptualization (lead).

DATA AVAILABILITY STATEMENT
Information, data and photographs will be provided if requested.

ORCID
Sina Rashedi https://orcid.org/0000-0003-0146-5611
Seyed Mohammad Kazem Aghamir https://orcid.org/0000-0003-1611-0362

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. Basu S, Tindall DJ. Androgen action in prostate cancer. Hormones Cancer. 2010;1(5):223-228.
3. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006;99(2):333-344.
4. Abd Wahab NA, Lajis NH, Abas F, Othman I, Naidu R. Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer. Nutrients. 2020;12(3):679.
5. Aghamir SMK, Shafiee G, Ebrahimi M, et al. Comparison on diagnostic accuracy of prostate cancer detection tools: a systematic review and meta-analysis. Translat Res Urol. 2019;1(1):27-39.
6. Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As$_2$O$_3$) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-3360.
7. Mirzaei A, Zareian Baghdadbab L, Khorrami MH, Aghamir SMK. Arsenic trioxide; a novel therapeutic agent for prostate and bladder cancers. Translat Res Urol. 2019;1(1):1-7.
8. Lu M, Xia L, Luo D, Waxman S, Jing Y. Dual effects of glutathione-S-transferase pi on As$_2$O$_3$ action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene. 2004;23(22):3945-3952.
9. Rosenblatt AE, Burnstein KL. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Molec Endocrinol. 2009;23(3):412-421.
10. Tai S, Xu L, Xu M, et al. Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. Oncotarget. 2017;8(7):11206-11218.
11. Ji H, Li Y, Jiang F, et al. Inhibition of transforming growth factor beta/SMAD signal by Mir-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. Cancer Sci. 2014;105(12):1541-1549.
12. Wang ZY, Song J, Zhang DS. Nanosized As$_2$O$_3$/Fe$_3$O$_4$ complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol. 2009;15(24):2995-3002.
13. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2213-2217.
14. Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14(2):107-119.
15. Khatami F, Aghamir SMK, Salmaninejad A, Shivarani S, Khorrami MH, Biomarkers for prostate cancer diagnosis from genetic perspectives. Translat Res Urol. 2020;2(2):51-58.
16. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prevent. 2008;17(1):88-94.
17. Brown M, Hart C, Tawadros T, et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer. 2012;106(10):1689-1696.
18. Climent E, Benages D, Pedro-Botet J. Hydrophilic or lipophilic statins? Frontiers in Cardiovasc Med. 2021;8:491.
19. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100(21):1511-1518.
20. Yang L, Egger M, Plattner R, Klocker H, Eder IE. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology. 2011;77(6):1508 e1-1517.
21. Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtola TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. Biochem Biophys Res Comm. 2016;481(1-2):46-50.
22. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 2000;6(12):4957-4964.
23. Chiu HW, Chen YA, Ho SY, Wang YJ. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One. 2012;7(2):e31579.
24. Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As$_2$O$_3$) in the orthotropic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001;61(14):5432-5440.

25. Jadhav V, Ray P, Sachdeva G, Bhatt P. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines. Life Sci. 2016;148:41-52.

26. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J. Pharmacol. Exp. Therap. 2011;336(2):496-505.

27. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7(1):e30062.

28. Bañez LL, Klink JC, Jayachandran J, et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol. Biomarkers Prevent. 2010;19(3):722-728.

29. Deng J-L, Zhang R, Zeng Y, Zhu Y-S, Wang G. Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells. Cancer Manage Res. 2019;11:7231.

30. Alqudah MA, Mansour HT, Mhaidat N. Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1. Saudi Pharm J. 2018;26(2):191-197.

31. Chen B, Zhang M, Xing D, Feng Y. Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition. Biosci Rep. 2017;37(4).

32. Wang Z, Zhang L, Wan Z, et al. Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumourspheres of prostate cancer cells. Pathol Oncol Res. 2020;26(1):209-216.

33. Zheng X, Cui X-X, Gao Z, et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prevent Res. 2010;3(1):114-124.

34. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011;336(2):496-505.

35. Sadaf N, Kumar N, Ali M, Ali V, Bimal S, Haque R. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci. 2018;205:9-17.

36. Sun Y, Wang C, Wang L, Dai Z, Yang K. Arsenic trioxide induces apoptosis and the formation of reactive oxygen species in rat glioma cells. Cell Mol Biol Lett. 2018;23:13.

37. Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As$_2$O$_3$) on human breast cancer cells. J Cell Biochem. 2004;93(1):173-187.

38. Spamanato C, De maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935-941.

39. Khatami F, Aghamir SMK, Oncometabolites TSM. A new insight for oncology. Molec Genet Genomic Med. 2019;7(9).

40. Kitazawa H, Numakawa T, Adachi N, et al. Cyclophosphamide promotes cell survival via activation of intracellular signaling in cultured cortical neurons. Neurosci Lett. 2010;470(2):139-144.

41. Bauer G. Reactive oxygen and nitrogen species: efficient, selective, and interactive signals during intercellular induction of apoptosis. Anticancer Res. 2000;20(6b):4115-4139.

42. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-1337.

43. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 2002;21(2):319-327.

44. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004;23(3):786-794.

45. Mirzaei A, Akbari MR, Zadeh SST, Khatami F, Mashhadi R, Aghamir SMK. Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: an in-vitro study. Tissue Cell. 2022;74:101684.

46. Wu T-L, Wang J-S, Jianne B-P, et al. Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues. J Chinese Med Assoc. 2007;70(9):380-384.

47. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006;6(8):819-830.

48. Al-Husein B, Goc A, Somanath PR. Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J Cell Physiol. 2013;228(11):2139-2148.

49. Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011;25(1):41-47.

How to cite this article: Mirzaei A, Rashedi S, Akbari MR, Khatami F, Aghamir SMK. Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. J Cell Mol Med. 2022;26:2728-2740. doi:10.1111/jcmm.17286